The rationale was based on the observation that the rs12459419 C > T single nucleotide polymorphism, associated with decreased CD33 surface expression, is present in more than 50% of AML patients.307–309 The lintuzumab-enhanced CD33 CAR-T cells are capable of recognizing low-antigen-density AML. Here, CD33 is linked to acute myeloid leukemia.